Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kyowa Kirin

- PMLiVE

Shire separates out neuroscience as it considers its future

Follows last year's strategic review at the Irish biotechnology firm

Magic of Lucid targets rare and specialist diseases

Lucid Group, the award-winning global medical communications company with offices in London, Buckinghamshire, Macclesfield and New York, has announced the launch of a new agency specialising in rare and specialist...

Lucid Group Communications Limited

EphMRA 2017 round up

We were delighted to present, exhibit and sponsor this year’s EphMRA Annual Conference in Amsterdam, Netherlands.

Research Partnership

- PMLiVE

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

Lucid Group Communications Limited

Shire Basingstoke

Shire finally bags EU approval for rare disease drug Natpar

Becomes first licenced treatment for hypoparathyroidism in Europe

Blending medical and digital for effective rare disease campaigns

The fundamentals of building a collaborative medical and digital team

National Institute for Health and Care Excellence NICE logo

Amicus gets NICE green light for Fabry drug

Oral therapy alternative Galafold approved for routine NHS use

- PMLiVE

NICE blocks second Alexion rare disease drug in a week

Says high cost and “considerable uncertainties” over long-term benefits prohibit routine NHS use

ABPI London offices

UK pharma slams new drug evaluation plans

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

ABPI London offices

UK pharma slams new drug evaluation plans

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

- PMLiVE

A rare talent

Shire’s Sebastian Stachowiak on dealing with change and working for a fit-for-purpose orphan drug environment

Biogen Idec building

FDA approves Biogen’s Spinraza for spinal muscular atrophy

Analysts predict blockbuster sales as drug is priced at $750,000 for first year of treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links